ClinicalTrials.gg
RecruitingNCT06333340Updated Apr 1, 2026

Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery

An interventional study of Oxytocin and Carbetocin in Post Partum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.

Planned enrollment
26th of 64
160 · median 108
Started
2025
with 2 others
No phase
37 of 64
6 open now
Registered
57th of 64
by date
Lead sponsor
22 of 64
Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 26th largest by planned enrollment, is one of 3 that started in 2025, is one of 37 with no phase, and was the 57th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing oxytocin in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH.

This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa.

The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.

Read the detailed description

Postpartum hemorrhage (PPH) is a potentially life-threatening complication and one of the leading causes of maternal mortality. It has been estimated that one in every five maternal deaths occurs due to PPH globally. Primary PPH is predominantly caused by uterine atony or inadequate contraction of the uterus after childbirth. Active management of the third stage of labor involves prophylactic administration of a uterotonic agent before delivery of the placenta, as well as delayed cord clamping and controlled traction of the umbilical cord. The uterotonic administration remains the most essential component in terms of preventing PPH.

Oxytocin, a synthetic pituitary hormone, is the most commonly used first-line uterotonic drug. However, because of the short half-life (3-17 min), a continuous intravenous infusion is necessary to maintain uterotonic activity. Carbetocin is a synthetic oxytocin analog that binds with a similar affinity to the oxytocin receptors in the myometrium. Carbetocin produces stronger and more sustained action compared to oxytocin and has a longer half-life than oxytocin, thus reducing the requirement for an infusion after the initial dose. Recently published guidelines from the Society of Obstetrics and Gynecology (SOGC) have stated that Carbetocin should be considered as a first-line agent for the prevention of PPH after cesarean delivery (CD). The international consensus statement on the use of uterotonic agents has also recommended carbetocin as an alternative to oxytocin infusion during CD due to its longer duration of action.

Trials comparing carbetocin with oxytocin in CD have shown mixed results on superiority of carbetocin over oxytocin for the need for additional uterotonics and amount of blood loss, however, no significant effect on blood loss >1000 ml could be found. Most of the trials evaluating the prophylactic role of oxytocin and carbetocin after CD have focused on the low-risk PPH population. The incidence of biological risk factors for uterine atony such as multiple gestation (due to assisted reproductive techniques), and obesity has progressively increased in developed countries. There is still a lack of high-quality trials on the efficacy of carbetocin in high-risk parturients undergoing CD.

In this study, the investigators aim to compare the efficacy of carbetocin 100 mcg with oxytocin 5 IU bolus followed by continuous infusion of 250 mIU/min over 4 hours at elective CD in parturients with risk factors for uterine atony.

The comparative data is still lacking for both the agents as first-line uterotonics for patients having a high risk for uterine atony undergoing cesarean delivery. The result of this trial regarding the relative uterotonic efficacy and safety of the standardized prophylactic doses of both agents (carbetocin and oxytocin) will form the evidence base for future guidelines in high-risk parturients.

03

Conditions studied

  • Post Partum Hemorrhage

Browse trials for

Keywords

  • oxytocin
  • carbetocin
  • cesarean delivery
  • pregnancy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria - Any one or more of the risk factors for uterine atony:

  • Overdistended uterus due to:

    • Polyhydramnios (amniotic fluid index >24 cm)
    • Fetal macrosomia reported on prenatal ultrasound >90th centile or > 4000 gm
    • Multiple gestation
  • History of uterine atony/PPH (documented with blood loss of >1000 ml, blood transfusion, use surgical methods such as Bakri balloon, B-Lynch sutures, uterine artery ligation or embolization)
  • Obesity with (BMI) >40 kg/m2
  • Diabetes mellitus on treatment
  • Preeclampsia on treatment
  • Placenta previa

Exclusion criteria:

  • Valvular heart disease, arrhythmias, or heart failure
  • Placenta accreta spectrum
  • Bleeding disorder
  • Anemia (\<100 g/dl)
  • Allergy or sensitivity to oxytocin or carbetocin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Oxytocin 5IU

    IV oxytocin 5 IU diluted in 10 mL normal saline over 1 min followed by continuous infusion of 250 mIU/min over 4 hours.

    Drug: Oxytocin

  • Active comparator
    Carbetocin 100mcg

    IV carbetocin 100 mcg diluted in 10 mL normal saline over 1 min followed by placebo infusion for 4 hours after the delivery of the fetus.

    Drug: Carbetocin

Interventions

  • Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.

    Also known as: Pitocin

  • Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.

    Also known as: Duratocin

06

What researchers measure

Primary outcomes

  1. Proportion of parturients requiring additional uterotonic agents intraoperatively

    The proportion of patients who are administered additional uterotonic agents intraoperatively will be divided by the total number of patients assigned to the same treatment arm, for each of the 2 groups: oxytocin and carbetocin.

    Time frame: 90 minutes

Secondary outcomes

  1. Uterine Tone 3 minutes

    The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 3 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.

    Time frame: 3 minutes

  2. Uterine Tone 5 minutes

    The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 5 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.

    Time frame: 5 minutes

  3. Uterine Tone 10 minutes

    The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 10 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.

    Time frame: 10 minutes

  4. Calculated blood loss (CBL)

    Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 24 hours after the cesarean section.

    Time frame: 24 hours

  5. Semi-quantitative blood loss (SQBL)

    Blood loss measured in the operating room by volume (ml)

    Time frame: 2 hours

  6. Presence of blood transfusion

    Number of units of blood product administered post-delivery

    Time frame: 24 hours

  7. Number of patients with ICU admission

    Admission to the intensive care unit for bleeding post partum

    Time frame: 24 hours

  8. Number of patients with conservative surgical methods to manage post partum hemorrhage

    Bakri balloon/B-Lynch sutures used intraoperatively

    Time frame: 2 hours

  9. Number of patients with radiological methods used to manage post partum hemorrhage

    Uterine artery embolization used intraoperatively.

    Time frame: 2 hours

  10. Number of patients with surgical post partum hemorrhage management measures

    Re-exploration for bleeding/uterine artery ligation/hysterectomy

    Time frame: 2 hours

  11. Number of patients with hypotension defined as systolic blood pressure less than 80% of baseline

    Systolic blood pressure \< 80% of baseline, at any time during surgery

    Time frame: 2 hours

  12. Number of patients with hypertension defined as systolic blood pressure greater than 120% of baseline

    Systolic blood pressure \> 120% of baseline, at any time during surgery

    Time frame: 2 hours

  13. Number of patients with tachycardia defined as heart rate greater than 130% of baseline

    Heart rate \> 130% of baseline, at any time during surgery

    Time frame: 2 hours

  14. Number of patients with bradycardia defined as heart rate less than 70% of baseline

    Heart rate \< 70% of baseline, at any time during surgery

    Time frame: 2 hours

  15. Presence of ventricular tachycardia: ECG

    Presence of ventricular tachycardia as recorded by ECG, at any time during surgery

    Time frame: 2 hours

  16. Presence of atrial fibrillation: ECG

    Presence of atrial fibrillation as recorded by ECG, at any time during surgery

    Time frame: 2 hours

  17. Presence of atrial flutter: ECG

    Presence of atrial flutter as recorded by ECG, at any time during surgery

    Time frame: 2 hours

  18. Presence of nausea: questionnaire

    The presence of nausea at any time during surgery, as reported by the patient

    Time frame: 2 hours

  19. Presence of vomiting: questionnaire

    The presence of vomiting at any time during surgery, as reported by the patient

    Time frame: 2 hours

  20. Number of patients with chest pain: questionnaire

    Any presence of chest pain, at any time during surgery, as reported by the patient

    Time frame: 2 hours

  21. Number of patients with shortness of breath: questionnaire

    Any presence of shortness of breath, at any time during surgery, as reported by the patient.

    Time frame: 2 hours

  22. Number of patients with headache: questionnaire

    Any presence of headache, at any time during surgery, as reported by the patient.

    Time frame: 2 hours

  23. Number of patients with flushing: questionnaire

    Any presence of flushing, at any time during surgery.

    Time frame: 2 hours

  24. Additional uterotonics administered up to 24 hours post delivery: questionnaire

    Were any additional uterotonics administered up to 24 hours post delivery: yes or no Detailed description of any medication and dosage recorded.

    Time frame: 24 hours

  25. Obstetric Quality of Recovery-10 (ObsQoR-10) score 24 hours

    ObsQoR-10 score at 24 hours. There are 10 questions, and the results are tabulated out of 100. The higher the overall score out of 100, the better quality of recovery a patient is experiencing.

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Mount Sinai Hospital
    Toronto, Ontario M5G1X5, Canada
    Recruiting
    • Mrinalini Balki, MD · Contactmrinalini.balki@uhn.ca · 416-586-4800
    • Narinder Singh, MD · Sub investigator
    • Ronald George, MD · Sub investigator
    • Kristi Downey, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 23 months is above that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 27, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06333340
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Jan 14, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 1, 2026

Study contacts

Mrinalini Balki, MD
Contact
mrinalini.balki@uhn.ca
416-586-4800 ext. 5270
Mrinalini Balki, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxytocin · Carbetocin

Start the discussion